Plain-English translation of NCT07632118 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether combining radiation therapy with a chemotherapy regimen called GX (gemcitabine and capecitabine) after pancreatic cancer surgery can help prevent cancer from coming back in high-risk patients. Some patients will receive chemotherapy alone, while others will receive three cycles of chemotherapy first, then radiation combined with a pill form of the medication, followed by additional chemotherapy cycles. The goal is to see if this combined approach helps people live longer and stay cancer-free.
After pancreatic cancer surgery, cancer often comes back, especially in patients with certain high-risk features. While chemotherapy after surgery is standard treatment, doctors are unsure whether adding radiation therapy can further improve survival and reduce recurrence in these high-risk patients. This trial will help answer that important question.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups: either chemotherapy alone for six cycles (each cycle is 21 days), or three cycles of chemotherapy followed by radiation therapy given at the same time as a daily oral medication, then three more cycles of chemotherapy. Participation involves regular hospital or clinic visits for treatment sessions, blood tests to monitor your health and how your body is tolerating the treatment, and imaging scans (like CT or MRI) to check whether the cancer has returned. The entire treatment period typically lasts several months.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China